The work will be performed as a sub-contractor to Leidos, which has been contracted by the U.S. Air Force to provide research, development, test and evaluation and advisory and assistance services related to research and development efforts within the chemical, biological, radiological and nuclear defense, homeland defense and security, critical infrastructure protection, weapons of mass destruction, biometrics, medical, cultural studies and alternative energy focus areas.
"The scope of work under the contract will encompass new and emerging adversary threats that could degrade U.S. and allied capabilities, new or extended capabilities in existing military systems and new technology applications to military problems," AIBioTech said.
Leidos is one of a dozen companies eligible to bid for work for the Department of Defense Information Analysis Centers, which are administered by the Defense Technical Information Center.
"AIBioTech's strengths in understanding and addressing issues of bio-defense and its recognized expertise in state-of-the-art life science technologies were major factors in our selection to the Leidos team," said Robert B. Harris, president and chief science officer of AIBioTech and program manager at AIBioTech for the new contract effort. "We are pleased to support the efforts of Leidos in meeting the challenges presented by DTIC."